PNC-27 (10mg)

Mechanism of Action: How PNC-27 (10mg) Works

PNC-27 binds to HDM-2, a surface marker on some malignant cells:

• HDM-2 Binding: Recognizes cancer-cell membranes
• Pore Formation: Creates breaches in tumor cell structure
• Selective Apoptosis: Healthy cells remain unaffected
• Immune Exposure Enhancement: Dead tumor cells → increased signaling
• Non-Genomic Pathway: Does not modify DNA or internal cell function

Result: direct cancer-cell death without systemic toxicity pathways.

Clinical Dosing Guide for Providers

For licensed research medical professionals only.
This compound is not approved as a drug treatment for cancer.

Suggested Dosing (Investigational)

• Clinical research models: varied exposure schedules
• Administration frequency determined by investigational protocol
• Duration: Based on tumor response evaluation

Administration Notes

• Route: Subcutaneous or intratumoral per research design
• Requires strict oversight due to investigational status

Common Investigational Stacks

• Checkpoint inhibitors
• Cellular therapy protocols
• Angiogenesis-inhibitor combinations

Reconstitution & Storage

• Reconstitute with bacteriostatic water
• Refrigerate post-mixing
• Stable ~30 days with cold-chain compliance

Ideal Candidate Profile

Strictly research-based — not for standard clinical care.

Potential Use Cases (Investigational)

• Tumors with high HDM-2 expression
• Therapy-resistant or advanced disease models
• Preclinical laboratory study subjects

Use With Caution

• Immunocompromised subjects require additional monitoring
• Not indicated for general use outside of experimental settings

Potential Side Effects

Reported during investigational use:

• Mild injection-site irritation
• Temporary inflammation at tumor site
• Transient flu-like symptoms
• Rare: immune sensitivity or cytokine flare

Frequently Asked Questions

1. What is PNC-27 used for?
Investigation into selective cancer-cell targeting and lysis.

2. Does it harm healthy cells?
Preclinical findings show selectivity for HDM-2 positive tumor cells.

3. Is it FDA approved?
No — investigational only.

4. What cancers express HDM-2?
Observed in multiple tumor lines under study.

5. Is it chemotherapy?
No — peptide-based cell-membrane disruption.

6. Does it replace standard treatment?
No — experimental therapy only.

7. Can it be used with immunotherapy?
Often studied in combined approaches.

8. How fast does response occur?
Varies by tumor model and research parameters.

9. Can it be legally prescribed?
Only in allowed investigational medical contexts.

10. How is it stored?
Refrigerated after reconstitution.

PNC-27 vs Similar Research Peptides

• vs PNC-28:
  PNC-27 targets cancer-cell membrane via HDM-2 binding more selectively.
• vs Chemotherapeutics:
  Potential for reduced systemic toxicity.
• vs Immunotherapy:
  Targeted cell lysis, not immune checkpoint modulation.

Research & Evidence Overview

Preclinical research indicates:

• Effective lysis of HDM-2 positive cancer cells
• Minimal damage to healthy cells
• Potential for multi-cancer applicability
• Strong rationale for combination-study development

A major focus in emerging cancer-selective peptide science.

Product & Purity Assurance

99% purity

• COA + endotoxin validated
• cGMP peptide manufacturing
• Provider-limited investigational access

Legal & Medical Disclaimer

For qualified research medical professionals only. Not intended to diagnose, treat, or cure any condition.